# Commission Regulation (EU) No 122/2013Show full title

Commission Regulation (EU) No 122/2013 of 12 February 2013 amending Regulation (EC) No 1950/2006 establishing, in accordance            with Directive 2001/82/EC of the European Parliament and of the Council on the Community code relating to veterinary medicinal            products, a list of substances essential for the treatment of equidae (Text with EEA relevance)         

        - Previous
        - Next

U.K.

# Commission Regulation (EU) No 122/2013                     

# of 12 February 2013

# amending Regulation (EC) No 1950/2006 establishing, in accordance with Directive 2001/82/EC of the European Parliament and                        of the Council on the Community code relating to veterinary medicinal products, a list of substances essential for the treatment                        of equidae                     

# (Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code                           relating to veterinary medicinal products(1), and in particular Article 10(3) thereof,                        

Whereas:

(1)Commission Regulation (EC) No 1950/2006(2) established a list of substances essential for the treatment of equidae which, by way of derogation from Article 11 of Directive                              2001/82/EC, may be administered to equidae intended for slaughter for human consumption subject to a withdrawal period of                              not less than six months.

(2)Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community procedures for                              the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin(3) amended Article 10(3) of Directive 2001/82/EC in order to include in the list of substances referred to in that Article substances                              which bring added clinical benefit compared to other treatment options available for equidae, hereinafter ‘substances bringing                              added clinical benefit’, in addition to essential substances.

(3)A substance should only be included in the list as a ‘substance bringing added clinical benefit’ where it provides a clinically                              relevant advantage based on improved efficacy or safety or a major contribution to treatment. This may be the result, inter                              alia, of different modes of actions, different pharmacokinetic or pharmacodynamic profiles, different lengths of treatment                              or different routes of administration.

(4)Substances listed in the Annex to Commission Regulation (EU) No 37/2010 of 22 December 2009 on pharmacologically active substances                              and their classification regarding maximum residue limits in foodstuffs of animal origin(4) should not appear on the list of essential substances and substances bringing added clinical benefit. Therefore, it is necessary                              to amend the list in the Annex to Regulation (EC) No 1950/2006 to remove from that list any substances listed in Regulation                              (EU) No 37/2010.

(5)It is also appropriate to remove from the list in the Annex to Regulation (EC) No 1950/2006 several substances identified                              as alternatives to the substances listed, which are not available for the treatment of horses because they are not listed                              as ‘essential substances’ or ‘substances bringing added clinical benefit’ under Regulation (EC) No 1950/2006 nor listed in                              the Annex to Regulation (EU) No 37/2010.

(6)Due to changes in Union legislation since the adoption of Regulation (EC) No 1950/2006, the references in that Regulation                              to the relevant legislation on control mechanisms for equidae and on maximum residue limits should be updated.

(7)The amended list set out in the Annex to this Regulation has been subject to a scientific evaluation carried out by the Committee                              for Veterinary Medicinal Products of the European Medicines Agency established by Regulation (EC) No 726/2004 of the European                              Parliament and of the Council(5).

(8)Regulation (EC) No 1950/2006 should be amended accordingly.

(9)The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal                              Products,

HAS ADOPTED THIS REGULATION:

# Article 1U.K.

Regulation (EC) No 1950/2006 is amended as follows:

the title of Regulation (EC) No 1950/2006 is replaced by the following:

‘Commission Regulation (EC) No 1950/2006 of 13 December 2006 establishing, in accordance with Directive 2001/82/EC of the European                                 Parliament and of the Council on the Community code relating to veterinary medicinal products, a list of substances essential                                 for the treatment of equidae and of substances bringing added clinical benefit’;

Article 1 is replaced by the following:

# ‘Article 1

The list of substances essential for the treatment of equidae, hereinafter “essential substances”, as well as of substances                                 which bring added clinical benefit compared to other treatment options available for equidae, hereinafter “substances bringing                                 added clinical benefit”, applicable by way of derogation from Article 11 of Directive 2001/82/EC, is set out in the Annex                                 to this Regulation.’;                           

in Article 2, the second subparagraph is replaced by the following:

‘Substances bringing added clinical benefit may be used, for the specific disease conditions, treatment needs or zootechnical                                 purposes specified in the Annex, where they provide a clinically relevant advantage based on improved efficacy or safety or                                 a major contribution to treatment compared to medicinal products authorised for equidae or referred to in Article 11 of Directive                                 2001/82/EC.                           

For the purposes of the first and second subparagraphs, the alternatives listed in the Annex shall be considered.’;                           

Articles 3 and 4 are replaced by the following:

# ‘Article 3

1.Essential substances and substances bringing added clinical benefit shall be used only in accordance with Article 10(1) of                                    Directive 2001/82/EC.                           

2.The details of a treatment with essential substances shall be recorded in accordance with the instructions laid down in Section                                    IX of the identification document for equidae set out in Commission Regulation (EC) No 504/2008(6).                           

# Article 4

Any substance that is entered in one of the lists in the Annex to Commission Regulation (EU) No 37/2010(7), or the use of which for equidae is prohibited by Union legislation, shall no longer be used for the purposes of this Regulation.’;                           

in Article 5, paragraph 2 is replaced by the following:

‘2.Where Member States or veterinary professional associations request the Commission to amend the list set out in the Annex,                                    they shall duly substantiate their request and include any relevant scientific data available.’;                           

the Annex to Regulation (EC) No 1950/2006 is replaced by the Annex to this Regulation.

# Article 2U.K.

This Regulation shall enter into force on the third day following that of its publication in the *Official Journal of the European Union*.                  

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 12 February 2013.

*For the Commission*                            

*The President*                            

José Manuel Barroso                            

## ANNEXU.K.

### “ANNEX**List of substances essential for the treatment of equidae and substances bringing added clinical benefit compared to other                           treatment options available for equidae**

The withdrawal period for each of the substances on the following list shall be six months.

1

OJ L 311, 28.11.2001, p. 1.                           

2

OJ L 367, 22.12.2006, p. 33.                           

3

OJ L 152, 16.6.2009, p. 11.                           

4

OJ L 15, 20.1.2010, p. 1.                           

5

OJ L 136, 30.4.2004, p. 1.                           

6

OJ L 149, 7.6.2008, p. 3.                           

7

OJ L 15, 20.1.2010, p. 1.’;